21 CFR 211.176 - Penicillin Contamination

What it says

If a reasonable possibility exists that a non-penicillin drug product has been exposed to cross-contamination with penicillin, the non-penicillin drug product must be tested for the presence of penicillin, and may not be marketed if detectable levels are found, using methods sensitive enough to detect contamination at established action levels.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• This is one of the few Part 211 provisions naming a specific substance directly, reflecting penicillin's unique and well-documented history of causing severe allergic reactions in sensitised individuals even at extremely low exposure levels.
• The obligation is triggered by reasonable possibility of exposure, not confirmed contamination, meaning shared facilities, equipment or air handling systems with any penicillin manufacturing history require proactive testing rather than waiting for a specific incident.
• This provision is the specific regulatory root of the broader industry practice of maintaining complete facility separation for penicillin and certain other highly sensitising compound production.

What FDA inspectors look for

• Whether any historical or current penicillin manufacturing activity at a facility has been assessed for reasonable possibility of cross-contamination to other products manufactured there.
• Whether testing methods used to detect penicillin cross-contamination have adequate sensitivity relative to the established action levels.
• Whether facility and equipment separation decisions reflect a genuine, documented risk assessment specific to penicillin's unique sensitisation profile.

Related regulations